Anti‐TIF1‐γ‐associated dermatomyositis associated with recurrent metastatic triple‐negative breast cancer: Dramatic clinical response to sacituzumab govitecan
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2024
DOI: 10.1111/ddg.15399 ↗Kurz gefasst
Leserbrief in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2024. Verfasst von Wei-Yao Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antibodies, Monoclonal, Humanized, Dermatomyositis. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
- Department of Dermatology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Dermatology, Kaohsiung Municipal Siaogang Hospital, Kaohsiung, Taiwan.
ORCID-Profile: Wei-Yao Wang
Zitieren
APA
Wang, W. Y., Lee, C. Y., & Hu, S. C. (2024). Anti‐TIF1‐γ‐associated dermatomyositis associated with recurrent metastatic triple‐negative breast cancer: Dramatic clinical response to sacituzumab govitecan. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15399
Vancouver
Wang WY, Lee CY, Hu SC. Anti‐TIF1‐γ‐associated dermatomyositis associated with recurrent metastatic triple‐negative breast cancer: Dramatic clinical response to sacituzumab govitecan. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2024. doi:10.1111/ddg.15399
BibTeX
@article{Wang2024,
author = {Wang, Wei-Yao and Lee, Chin-Yu and Hu, Stephen Chu-Sung},
title = {Anti‐TIF1‐γ‐associated dermatomyositis associated with recurrent metastatic triple‐negative breast cancer: Dramatic clinical response to sacituzumab govitecan},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2024},
doi = {10.1111/ddg.15399}
}
EUVIMED